4.3 Review

Cannabis based medicines and cannabis dependence: A critical review of issues and evidence

Journal

JOURNAL OF PSYCHOPHARMACOLOGY
Volume 35, Issue 7, Pages 773-785

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/0269881120986393

Keywords

Medical cannabis; tetrahydrocannabinol; cannabidiol; dependence; cannabis use disorder

Funding

  1. UK Medical Research Council [MR/P012728/1]
  2. UK Department of Health
  3. National Institute for Health Research (NIHR) UCLH Biomedical Research Centre (BRC)
  4. NIHR BRC

Ask authors/readers for more resources

This article reviews the current research on medical cannabis, focusing on the main issues related to medical cannabis and dependence. Medical and recreational cannabis use differ significantly, highlighting the need for further research to understand if medical cannabis can lead to dependence.
Cannabis has been legalised for medical use in an ever-increasing number of countries. A growing body of scientific evidence supports the use of medical cannabis for a range of therapeutic indications. In parallel with these developments, concerns have been expressed by many prescribers that increased use will lead to patients developing cannabis use disorder. Cannabis use disorder has been widely studied in recreational users, and these findings have often been projected onto patients using medical cannabis. However, studies exploring medical cannabis dependence are scarce and the appropriate methodology to measure this construct is uncertain. This article provides a narrative review of the current research to discern if, how and to what extent, concerns about problems of dependence in recreational cannabis users apply to prescribed medical users. We focus on the main issues related to medical cannabis and dependence, including the importance of dose, potency, cannabinoid content, pharmacokinetics and route of administration, frequency of use, as well as set and setting. Medical and recreational cannabis use differs in significant ways, highlighting the challenges of extrapolating findings from the recreational cannabis literature. There are many questions about the potential for medical cannabis use to lead to dependence. It is therefore imperative to address these questions in order to be able to minimise harms of medical cannabis use. We draw out seven recommendations for increasing the safety of medical cannabis prescribing. We hope that the present review contributes to answering some of the key questions surrounding medical cannabis dependence.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Psychiatry

Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?

Chandni Hindocha, Diego Quattrone, Tom P. Freeman, Robin M. Murray, Valeria Mondelli, Gerome Breen, Charles Curtis, Celia J. A. Morgan, H. Valerie Curran, Marta Di Forti

TRANSLATIONAL PSYCHIATRY (2020)

Review Clinical Neurology

Medical cannabis in the UK: From principle to practice

Anne Katrin Schlag, David S. Baldwin, Michael Barnes, Steve Bazire, Rachel Coathup, H. Valerie Curran, Rupert McShane, Lawrence D. Phillips, Ilina Singh, David J. Nutt

JOURNAL OF PSYCHOPHARMACOLOGY (2020)

Article Substance Abuse

Unknown population-level harms of cannabis and tobacco co-use: if you don't measure it, you can't manage it

Chandni Hindocha, Erin A. McClure

Summary: This paper highlights the challenges in collecting co-use data and provides recommendations for terminology and assessment of co-use. It suggests incorporating cannabis-tobacco co-use assessments in clinical studies to understand their impact on health outcomes.

ADDICTION (2021)

Article Substance Abuse

Cannabis use and co-use in tobacco smokers and non-smokers: prevalence and associations with mental health in a cross-sectional, nationally representative sample of adults in Great Britain, 2020

Chandni Hindocha, Leonie S. Brose, Hannah Walsh, Hazel Cheeseman

Summary: In Great Britain in 2020, approximately 7.1% of adults reported using cannabis in the past year, with tobacco smokers having greater odds of cannabis use compared to non-smokers. Co-administration of cannabis and tobacco was common, with mental health problems being particularly prevalent among dual users.

ADDICTION (2021)

Article Clinical Neurology

Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis

Abigail M. Freeman, Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia J. A. Morgan, Tom P. Freeman, Rob Saunders, H. Valerie Curran

Summary: Increased frequency of cannabis use may reduce the intensity of subjective and psychosis-like effects of THC, with weak moderating effects on acute memory impairment. Trait schizotypy does not influence THC's psychotomimetic effects.

JOURNAL OF PSYCHOPHARMACOLOGY (2021)

Article Clinical Neurology

Stimulating meditation: a pre-registered randomised controlled experiment combining a single dose of the cognitive enhancer, modafinil, with brief mindfulness training

Emily M. Thomas, Tom P. Freeman, Patrick Poplutz, Kane Howden, Chandni Hindocha, Michael Bloomfield, Sunjeev K. Kamboj

Summary: The study found that modafinil acutely increased state mindfulness and improved sustained attention, but did not enhance the effects of mindfulness training. However, participants receiving modafinil engaged in more strategy practice during follow-up, indicating potential benefits for integrating modafinil as an adjunct to mindfulness-based treatments.

JOURNAL OF PSYCHOPHARMACOLOGY (2021)

Editorial Material Ethics

Some Contributions on How to Formulate Drug Policies and Provide Evidence-Based Regulation

S. Rolles, D. J. Nutt, A. K. Schlag

AMERICAN JOURNAL OF BIOETHICS (2021)

Article Neurosciences

Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics

Anne Katrin Schlag, Saoirse E. O'Sullivan, Rayyan R. Zafar, David J. Nutt

Summary: The therapeutic potential of medical cannabis has greatly improved in recent years, although there is still controversy in some therapeutic indications. The discord between scientific evidence and patient reported outcomes highlights the urgent need for further research.

NEUROPHARMACOLOGY (2021)

Article Substance Abuse

The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use

Valentina Lorenzetti, Chandni Hindocha, Kat Petrilli, Paul Griffiths, Jamie Brown, Alvaro Castillo-Carniglia, Jonathan P. Caulkins, Amir Englund, Mahmoud A. ElSohly, Suzanne H. Gage, Teodora Groshkova, Antoni Gual, David Hammond, Will Lawn, Hugo Lopez-Pelayo, Jakob Manthey, Claire Mokrysz, Rosalie Liccardo Pacula, Margriet van Laar, Ryan Vandrey, Elle Wadsworth, Adam Winstock, Wayne Hall, H. Valerie Curran, Tom P. Freeman

Summary: The lack of an agreed international minimum approach to measuring cannabis use has hindered the integration of multidisciplinary evidence on the consequences of cannabis use. A group of 25 international expert cannabis researchers convened to discuss a framework for minimum standards to measure cannabis use globally. The expert consensus agreed upon a three-layered hierarchical framework, reflecting different research priorities and standards.

ADDICTION (2022)

Review Clinical Neurology

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science

Anne K. Schlag, Jacob Aday, Iram Salam, Jo C. Neill, David J. Nutt

Summary: This narrative review examines the evidence for potential harms of classic psychedelics and emphasizes the importance of adhering to high safety and ethical standards. The review finds that medical risks are often minimal and many negative perceptions of psychological risks lack scientific support.

JOURNAL OF PSYCHOPHARMACOLOGY (2022)

Letter Substance Abuse

The iCannTookit: a consensus-based, flexible framework for measuring contemporary cannabis use

Valentina Lorenzetti, Chandni Hindocha, Kat Petrilli, Paul Griffiths, Jamie Brown, Alvaro Castillo-Carniglia, Jonathan P. Caulkins, Amir Englund, Mahmoud A. El Sohly, Suzanne H. Gage, Teodora Groshkova, Antoni Gual, David Hammond, Will Lawn, Hugo Lopez-Pelayo, Jakob Manthey, Claire Mokrysz, Rosalie Liccardo Pacula, Margriet van Laar, Ryan Vandrey, Elle Wadsworth, Adam Winstock, Wayne Hall, H. Valerie Curran, Tom P. Freeman

ADDICTION (2022)

Article Substance Abuse

A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use

Steve Rolles, Anne Katrin Schlag, Fiona Measham, Lawrence Phillips, David Nutt, Daniel Bergsvik, Ole Rogeberg

Summary: This study concludes that state control of heroin is identified as the preferred policy option, despite other policy regimes scoring better on specific outcome criteria. The free market model scored better than decriminalization, while absolute prohibition scored worst on every criterion.

INTERNATIONAL JOURNAL OF DRUG POLICY (2021)

Article Psychology, Clinical

Cognitive fusion as a candidate psychological vulnerability factor for psychosis: An experimental study of acute increment 9-tetrahydrocannabinol (THC) intoxication

Katherine Newman-Taylor, Thomas Richardson, Rachel Lees, Katherine Petrilli, Helen Bolderston, Chandni Hindocha, Tom P. Freeman, Michael A. P. Bloomfield

Summary: Heavy cannabis use is associated with an increased risk of psychosis. This study found that cognitive fusion may be a key mechanism by which developmental trauma and schizotypy increase the risk of psychosis from cannabis use. Psychological interventions targeting cognitive fusion may be more effective in preventing cannabis-related psychosis.

PSYCHOSIS-PSYCHOLOGICAL SOCIAL AND INTEGRATIVE APPROACHES (2021)

No Data Available